A 12-month, multicenter, randomized, comparative, open-label study to investigate efficacy and safety of reduced level of TACrolimus with equimolar MyforTIC (Enteric coated Mycophenolate Sodium) or Mycophenolate Mofetil in de novo renal transplant recipients.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Mycophenolate sodium (Primary) ; Mycophenolate mofetil; Tacrolimus
- Indications Transplant rejection
- Focus Pharmacodynamics
- Acronyms myTACTIC
- Sponsors Novartis
- 12 Feb 2014 Status changed to active, no longer recruiting according to Clinical Trials Registry - India.
- 27 Mar 2012 New trial record